| Size | Price | |
|---|---|---|
| Other Sizes |
| Targets |
6-Bromonicotinic acid is a precursor for the synthesis of Anabaseine derivatives. Anabaseine is a marine toxin that acts as a partial agonist at nicotinic acetylcholine receptors (nAChRs). These receptors are involved in neurotransmission in the central and peripheral nervous systems and are targets for the treatment of various neurological and psychiatric disorders including Alzheimer's disease, schizophrenia, and addiction. The compound's nicotinic acid core provides a scaffold for the development of nAChR ligands. The bromine atom at the 6-position allows for cross-coupling reactions to introduce various substituents that can modulate receptor affinity and selectivity. The compound may also serve as a precursor for other biologically active nicotinic acid derivatives. As a derivative of nicotinic acid (niacin, vitamin B3), the compound may have metabolic effects related to NAD biosynthesis.
|
|---|---|
| ln Vitro |
In vitro, 6-bromonicotinic acid is used as a drug intermediate for the synthesis of Anabaseine derivatives. It is a biochemical reagent that can be used as a biological material or organic compound for life science related research. In medicinal chemistry, it serves as a building block for the synthesis of nicotinic acid derivatives with potential therapeutic applications. Its bromine atom allows for cross-coupling reactions such as Suzuki, Heck, and Buchwald-Hartwig couplings, enabling the introduction of various substituents. The carboxylic acid group allows for amidation, esterification, and other transformations to produce a diverse range of compounds. In organic synthesis, it is used as a building block for creating complex molecules efficiently.
|
| ln Vivo |
In vivo activity is mediated through the derivatives of 6-bromonicotinic acid rather than the parent compound itself. Anabaseine derivatives synthesized from this compound are evaluated in animal models of neurodegenerative diseases and other neurological disorders. These compounds may act as nAChR agonists or modulators, affecting neurotransmitter release and cognitive function. The parent compound itself is not administered in vivo, as it is a synthetic intermediate rather than a pharmacological agent.
|
| Enzyme Assay |
Cell-free assays for 6-bromonicotinic acid are focused on its use as a chemical reagent. Standard protocols for cross-coupling reactions involving the compound include Suzuki coupling with boronic acids, Heck coupling with alkenes, and other palladium-catalyzed transformations. These reactions are typically carried out with a palladium catalyst, a base, and an appropriate solvent at elevated temperatures under an inert atmosphere. The reaction progress is monitored by TLC or HPLC, and the products are purified by column chromatography. For the synthesis of Anabaseine derivatives, the compound is used as a starting material in multi-step synthetic routes. The compound's reactivity can be studied using various analytical techniques including NMR spectroscopy, mass spectrometry, and HPLC.
|
| Cell Assay |
Cellular assays are not performed with the parent compound 6-bromonicotinic acid. Instead, its derivatives, such as Anabaseine derivatives, are evaluated in cell-based systems. For nAChR ligands, cell lines expressing nAChRs are treated with the derivatives, and receptor binding, ion flux, or other signaling endpoints are measured. The parent compound itself is not used as a test article in cell-based experiments due to its role as a synthetic building block.
|
| Animal Protocol |
Animal studies are not conducted with the parent compound 6-bromonicotinic acid. Its derivatives, such as Anabaseine derivatives, are evaluated in animal models of neurodegenerative diseases and other neurological disorders. The parent compound itself is not administered to animals, as it is a synthetic intermediate. Toxicity and pharmacological profiles for the parent compound are inferred from related nicotinic acid derivatives.
|
| ADME/Pharmacokinetics |
Pharmacokinetic data for 6-bromonicotinic acid are not available, as the compound is primarily a chemical intermediate rather than a drug candidate. With a molecular weight of 202.01 g/mol and a melting point of 200-203 °C, the compound would be expected to have moderate polarity and limited membrane permeability if administered. However, comprehensive pharmacokinetic studies including absorption, distribution, metabolism, and excretion have not been performed, as the compound is not intended for therapeutic use. For research purposes, the compound is typically handled as a neat chemical and not administered to living organisms for pharmacokinetic profiling.
|
| Additional Infomation |
6-Bromonicotinic acid is a research chemical, not an approved drug. It has no clinical trial or marketing approval status for therapeutic use. The compound is a brominated derivative of nicotinic acid that can be used as a drug intermediate for the synthesis of Anabaseine derivatives. It is a biochemical reagent that can be used as a biological material or organic compound for life science related research. The compound has a molecular formula of C6H4BrNO2 and a molecular weight of 202.01 g/mol. It appears as off-white plates with a melting point of 200-203 °C. It should be stored at room temperature in a cool and dark place, preferably below 15 °C.
|
| Molecular Formula |
C6H4BRNO2
|
|---|---|
| Molecular Weight |
202.01
|
| Exact Mass |
200.942
|
| CAS # |
6311-35-9
|
| PubChem CID |
238932
|
| Appearance |
Typically exists as solid at room temperature
|
| Density |
1.8±0.1 g/cm3
|
| Boiling Point |
343.3±27.0 °C at 760 mmHg
|
| Melting Point |
200-203 °C(lit.)
|
| Flash Point |
161.4±23.7 °C
|
| Vapour Pressure |
0.0±0.8 mmHg at 25°C
|
| Index of Refraction |
1.617
|
| LogP |
1.15
|
| Hydrogen Bond Donor Count |
1
|
| Hydrogen Bond Acceptor Count |
3
|
| Rotatable Bond Count |
1
|
| Heavy Atom Count |
10
|
| Complexity |
140
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
BrC1C([H])=C([H])C(C(=O)O[H])=C([H])N=1
|
| InChi Key |
JDJBRMNTXORYEN-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C6H4BrNO2/c7-5-2-1-4(3-8-5)6(9)10/h1-3H,(H,9,10)
|
| Chemical Name |
6-bromopyridine-3-carboxylic acid
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 4.9502 mL | 24.7512 mL | 49.5025 mL | |
| 5 mM | 0.9901 mL | 4.9502 mL | 9.9005 mL | |
| 10 mM | 0.4950 mL | 2.4751 mL | 4.9502 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
